Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP sequential sacubitril/valsartan for acute heart failure
ChiCTR1800015649Phase 4Not yet recruiting
- Sponsor
- Tianjin Union Medical Center
- Start
- Jun 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of nesiritide and sacubitril + valsartan in Acute Heart Failure (AHF) (3 arms), sponsored by Tianjin Union Medical Center. Primary endpoints: Left ventricular ejection fraction at 36 weeks, Left atrial volume at 36 weeks and 6 more. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
nesiritidesacubitril + valsartan
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on ChiCTR1800015649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015649.